nach oben

Erschienen in:

21.11.2022 | Arterielle Hypertonie | Zertifizierte Fortbildung Neurologie

Kopfschmerzen, Papillenödem, Sehstörungen

Diagnose und Therapie der idiopathischen intrakraniellen Hypertension

verfasst von: Dr. med. Focko L. Higgen

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Auszug

Die idiopathische intrakranielle Hypertension (IIH) ist durch eine intrakranielle Liquordruckerhöhung mit den Leitsymptomen Kopfschmerzen und durch ein Papillenödem hervorgerrufene Sehstörungen charakterisiert. Sie zählt zu den seltenen Erkrankungen, die jedoch aufgrund einer Zunahme der Risikofaktoren in der Gesellschaft an Bedeutung gewinnt. Die IIH tritt typischerweise bei übergewichtigen Frauen im gebärfähigen Alter auf. Die Pathogenese ist nicht endgültig geklärt. Die Symptome sind gleichzeitig suspekt für eine sekundäre intrakranielle Hypertension, weshalb die Diagnose erst nach Ausschluss mittels Bildgebung und anschließender Lumbalpunktion gestellt werden kann. Therapeutisch wird ein Stufenschema aus Gewichtsreduktion, medikamentöser Therapie, wiederholten Lumbalpunktionen und operativen Verfahren mit dem Ziel der Senkung des Liquordrucks empfohlen. …

Durcan FJ et al. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol. 1988;45(8):875-7

Radhakrishnan K et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol. 1993;50(1):78-80

Kesler A et al. Idiopathic intracranial hypertension and anticardiolipin antibodies. J Neurol Neurosurg Psychiatry. 2000;68(3):379-80

Curry WT et al. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988-2002. Neurosurgery. 2005;57(1):97-108; discussion 97-108

Bruce BB et al. Atypical idiopathic intracranial hypertension: normal BMI and older patients. Neurology. 2010 ;74(22):1827-32

Digre KB et al. Pseudotumor cerebri in men. Arch Neurol. 1988;45(8):866-72

Hoffmann J et al. Neues beim Pseudotumor cerebri (Idiopathische intrakranielle Hypertension). Aktuelle Neurologie. 2017;44:466-75

Ireland B et al. The search for causes of idiopathic intracranial hypertension. A preliminary case-control study. Arch Neurol. 1990;47(3):315-20

Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain. 1991;114 (Pt 1A):155-80

10.

Giuseffi V et al. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology. 1991;41(2 (Pt 1)):239-44

11.

Wall M et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol. 2014;71(6):693-701

12.

Condulis N et al.Pseudotumor cerebri: a presenting manifestation of Addison's disease. Clin Pediatr. 1997;36(12):711-3

13.

Sheldon RS et al. Hypoparathyroidism and pseudotumor cerebri: an infrequent clinical association. Can J Neurol Sci. 1987;14(4):622-5

14.

Biousse V et al. Anemia and papilledema. Am J Ophthalmol. 2003;135(4):437-46

15.

Lee AG et al. Sleep apnea and intracranial hypertension in men. Ophthalmology. 2002;109(3):482-5

16.

Green L, Vinker S, Amital H, Amir T, Bar-Dayan Y, Levi Y, et al. Pseudotumor cerebri in systemic lupus erythematosus. Semin Arthritis Rheum. 1995;25(2):103-8

17.

Celebisoy N et al. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand. 2002;106(6):367-70

18.

Glueck CJ et al. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med. 2003;142(1):35-45

19.

Chang D et al.Benign intracranial hypertension and chronic renal failure. Cleve Clin J Med. 1992;59(4):419-22

20.

Dotan G, Goldstein M, Stolovitch C, Kesler A. Pediatric Pseudotumor Cerebri Associated With Low Serum Levels of Vitamin A. J Child Neurol. 2013 Nov;28(11):1370-7

21.

Reeves GD, Doyle DA. Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship? J Pediatr Endocrinol Metab. 2002;15 Suppl 2:723-30

22.

Maneatis T et al. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab. 2000;13 Suppl 2:1035-44

23.

Friedman DI. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol. 2005;6(1):29-37

24.

Togha M et al. Prevalence of new-onset migraine in patients with idiopathic intracranial hypertension in comparison to the general population. Iran J Neurol. 2018;17(4):161-166

25.

Friedman DI et al. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology. 28;58(10):1551-3

26.

Leker RR, Steiner I. Features of dural sinus thrombosis simulating pseudotumor cerebri. Eur J Neurol. 1999;6(5):601-4

27.

Sylaja PN et al. Differential diagnosis of patients with intracranial sinus venous thrombosis related isolated intracranial hypertension from those with idiopathic intracranial hypertension. J Neurol Sci. 2003 15;215(1-2):9-12

28.

Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2012;83(5):488-94

29.

Johnston I, Kollar C, Dunkley S et al. Cranial venous outflow obstruction in the pseudotumour syndrome: incidence, nature and relevance. J Clin Neurosci. 2002;9(3):273-8.

30.

King JO et al. Manometry combined with cervical puncture in idiopathic intracranial hypertension. Neurology. 2002;58(1):26-30

31.

McGonigal A et al. Resolution of transverse sinus stenosis in idiopathic intracranial hypertension after L-P shunt. Neurology. 2004;62(3):514-5

32.

Friedman DI, Rausch EA. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology. 2002;58(10):1551-3

33.

The International Classification of Headache Disorders, 3rd edition (beta version) - PubMed [Internet]. [cited 2022 Oct 3]. Available from: https://pubmed.ncbi.nlm.nih.gov/23771276/

34.

Chari C, Rao NS. Benign intracranial hypertension - its unusual manifestations. Headache. 1991;31(9):599-600

35.

Corbett JJ et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol. 1982;39(8):461-74

36.

Thambisetty M et al. Fulminant idiopathic intracranial hypertension. Neurology. 2007. 16;68(3):229-32

37.

Liu GT, Glaser JS, Schatz NJ. High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri. Am J Ophthalmol. 1994;118(1):88-96

38.

Khoo KF, Kunte H. Olfactory dysfunction in patients with idiopathic intracranial hypertension. Neurology. 2014;82(2):189

39.

Yri HM et al. Cognitive function in idiopathic intracranial hypertension: a prospective case-control study. BMJ Open. 2014 8;4(4):e004376

40.

Wall M et al. Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Neurology. 2015;85(9):799-805

41.

Frisén L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry [Internet]. 1982 Jan [cited 2022 Sep 28];45(1):13-8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC491259/

42.

Wüllner U. LL 030 093 Idiopathische intrakranielle Hypertension 2019 - Deutsche Gesellschaft für Neurologie e. V. [Internet]. Deutsche Gesellschaft für Neurologie e. V. [cited 2022 Sep 28]. Available from: https://go.sn.pub/lLPWkz

43.

Kelly LP et al. Does bilateral transverse cerebral venous sinus stenosis exist in patients without increased intracranial pressure? Clin Neurol Neurosurg. 2013;115(8):1215-9

44.

Farb RI et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003;60(9):1418-24

45.

Degnan AJ et al. Pseudotumor cerebri: brief review of clinical syndrome and imaging findings. AJNR Am J Neuroradiol. 2011;32(11):1986-93

46.

Riggeal BD et al. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology. 2013;80(3):289-95

47.

Brodsky MC et al. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology. 1998;105(9):1686-93

48.

Agid R et al. Idiopathic intracranial hypertension: the validity of cross-sectional neuroimaging signs. Neuroradiology. 2006;48(8):521-7

49.

Friedman DI et al. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002 26;59(10):1492-5

50.

Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-65

51.

Wall M. Sensory visual testing in idiopathic intracranial hypertension: measures sensitive to change. Neurology. 1990;40(12):1859-64

52.

NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311(16):1641-51

53.

Sinclair A J et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;341:c2701

54.

Sugerman HJ et al. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology. 1995;45(9):1655-9

55.

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-16

56.

Piper RJ et al. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2015 7;(8):CD003434.

57.

Digre KB et al. Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial results. Neurology. 2015;84(24):2449-56

58.

Matthews YY. Drugs used in childhood idiopathic or benign intracranial hypertension. Arch Dis Child Educ Pract Ed. 2008;93(1):19-25

59.

Finsterer J et al. Topiramate resolves headache from pseudotumor cerebri. J Pain Symptom Manage. 2006;32(5):401-2

60.

Celebisoy N et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007;116(5):322-7

61.

Loring DW et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology. 2011;76(2):131-7

62.

Botfield HF et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9(404):eaan0972

63.

Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology. 1983;33(10):1386-8

64.

Mollan SP et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088-100

65.

Banta JT et al. Pseudotumor cerebri and optic nerve sheath decompression. Ophthalmology. 2000;107(10):1907-12

66.

Friedman DI. Cerebral venous pressure, intra-abdominal pressure, and dural venous sinus stenting in idiopathic intracranial hypertension. J Neuroophthalmol. 2006;26(1):61-4

67.

Rowe FJ et al. Visual outcome in a prospective study of idiopathic intracranial hypertension. Arch Ophthalmol. 1999;117(11):1571

68.

Kesler A et al. Idiopathic intracranial hypertension: risk of recurrences. Neurology. 2004;63(9):1737-9

69.

Taktakishvili O et al. Recurrent idiopathic intracranial hypertension. Ophthalmology. 2008;115(1):221

Titel: Kopfschmerzen, Papillenödem, Sehstörungen
Diagnose und Therapie der idiopathischen intrakraniellen Hypertension
verfasst von: Dr. med. Focko L. Higgen
Publikationsdatum: 21.11.2022
Verlag: Springer Medizin
Schlagwörter: Arterielle Hypertonie
Pseudotumor cerebri
Kopfschmerzen
Acetazolamid
Hypertonie
Hypertonie
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 11/2022
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-022-3047-0

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2022

Hilft Ketamin bei akuter Suizidalität?

Lecanemab gegen Alzheimer: Wie gut sind die Effekte wirklich?

Invasive Parkinson-Therapien: Empfehlungen und Einschränkungen im Überblick

Inhalatives Levodopa wirkt bei jedem Schweregrad

Migräneprophylaxe aus der Sicht einer Betroffenen

CGRP-Antikörper frühzeitig verabreichen: Können wir es uns leisten?